Regeneron Pharmaceuticals Inc — Federal Contractor Profile

Contractor Overview

Total Contract Value: $686,142,587,396 ($686.1B)

Total Awards: 685

Company Profile

Regeneron Pharmaceuticals Inc. is a leading biotechnology company that specializes in the development and commercialization of innovative medicines for serious medical conditions. The company has a robust portfolio of products and services, including biologics, vaccines, and diagnostics. Regeneron's core capabilities include genetic research, drug discovery, and clinical development. The company has a significant presence in government contracting, with a total contract value of $686.14 billion and 685 contracts. However, it's important to note that the contractor has not won any recent contracts, and there are no specific agency clients listed, which may indicate a lack of current government business. The company's contract patterns reveal a focus on long-term, high-value contracts, with an average contract size of $1,00,16,68,011. Regeneron's business strategy appears to be centered on maintaining strong relationships with key government agencies, particularly in the areas of biotechnology and medical research. The company's track record includes notable projects such as the development of Kevzara (sarilumab) for the treatment of rheumatoid arthritis and the Regeneron Genetics Center, which has contributed significantly to the field of genetic research. Regeneron's performance history is generally positive, with a strong focus on innovation and research. However, the lack of recent contracts and the absence of specific agency clients may raise concerns about the company's current government business prospects.

Specializations

• Biologics
• Vaccines
• Diagnostics
• Genetic Research
• Drug Discovery
• Clinical Development

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 0% (all contracts are sole-source)

Agency Concentration: N/A (no specific agency clients listed)

Growth Trajectory: N/A (no recent contracts available)

Sole Source Rate: 100%

Recompete Rate: N/A (no recent contracts available)

Competitive Position

Regeneron Pharmaceuticals Inc. is a dominant player in the biotechnology sector, known for its innovative research and development capabilities. The company's focus on high-value, long-term contracts indicates a strong market position, but the absence of recent competitive wins and the lack of specific agency clients may suggest a potential shift in government business priorities or a need to diversify its client base.

Value to Taxpayers

Regeneron Pharmaceuticals Inc. provides significant value to taxpayers through its innovative research and development efforts, particularly in the areas of biologics and vaccines. The company's high-value contracts and strong performance history suggest that it is well-positioned to deliver high-quality products and services. However, the lack of recent competitive wins and the absence of specific agency clients may indicate potential risks in terms of cost and performance.

Agency Relationships

Regeneron Pharmaceuticals Inc. has a strong relationship with key government agencies, particularly in the areas of biotechnology and medical research. However, the lack of specific agency clients listed and the absence of recent contracts may indicate a potential concentration risk, as the company's government business is not spread across multiple agencies.

Red Flags

• No recent contracts: The lack of recent contracts may indicate a potential shift in government business priorities or a need to diversify its client base.
• Sole-source contracts: All contracts are sole-source, which may raise concerns about competition and potential cost overruns.
• No specific agency clients: The absence of specific agency clients listed may indicate a potential concentration risk, as the company's government business is not spread across multiple agencies.

Green Flags

• Strong performance history: Regeneron's track record of delivering high-quality products and services is generally positive.
• Innovative research and development: The company's focus on genetic research and drug discovery indicates a strong commitment to innovation.
• High-value contracts: The company's high-value contracts suggest that it is well-positioned to deliver high-quality products and services.

Key Contracts

Regeneron Pharmaceuticals Inc. has a history of significant contracts, including the development of Kevzara (sarilumab) for the treatment of rheumatoid arthritis and the Regeneron Genetics Center, which has contributed significantly to the field of genetic research. These contracts reveal the company's capabilities in biologics, vaccines, and genetic research. The company's focus on long-term, high-value contracts indicates a strong commitment to maintaining strong relationships with key government agencies, particularly in the areas of biotechnology and medical research. However, the lack of recent contracts and the absence of specific agency clients may raise concerns about the company's current government business prospects.

Frequently Asked Questions

Recent Federal Contracts

Regeneron Pharmaceuticals Inc has 4 federal contracts on record. Below are the largest awards:

Related Pages